• V. Ranjani
  • K. Manigandan
  • Namasivayam Elangovan


Parkinson disease, Substantia nigra, Molecular docking, Lipinski, ADMET


Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. Etiology of PD is progressive loss of dopaminergic neurons in Substantia nigra pars compacta (SNpc). One of the pathological hallmarks of PD is the presence of intracellular proteinaceous substances termed ‘Lewy bodies' composed of aggregated alpha-synuclein which is responsible for its toxic effect on SNpc. Hence any therapeutic target which blocks α-synuclein aggregation will provide a new channel to cure PD.

Objective: The aim of the present study is to identify potent inhibitors (ligands) which binds to active site of α-synuclein and prevents self-association.

Methods: In this study, insilico molecular docking was done against α-synuclein using five plant derived compounds namely (a) stimovul (b) 7,8dihydroxycoumarin, (c) etorphine (d) propoxyphene and (e) pentazdine. These compounds were analyzed for their Lipinski and ADMET properties using Accelrys Discovery studio 3.5. Molecular docking was performed between ligand and protein using Lead IT.

Results: Results revealed that the best fit ligands against active site of α-synuclein were identified as Stimovul with a docking score of -4.5122 and the interacting amino acids were found to be SER 87 and VAL 95 followed by other compounds.

Conclusion: These compounds which have the ability to bind to α-Synuclein insilico can be further developed using invitro and in vivo studies as a potent anti-parkinson drug.  

Keywords: Parkinson disease, Substantia nigra, Molecular docking, Lipinski, ADMET.


Download data is not yet available.


1. George JL, Mok S, Moses D, Wilkins S, Bush AI, Cherny RA et al. Targeting the progression of Parkinson’s Disease Current Neuropharmacology 2009;7 :9-36.

Rose F, Hodak M, Bernholc J. Mechanism of copper (II) - induced misfolding of parkinson’s disease protein Sci Rep 2011; 1: 11.

William Dauer and Serge Przedborski. Parkinson’s Disease: Mechanisms and models Neuron. 2003; 39 :889-909.

Mikkilineni S, Castelvetri IC, M.Cahill C, Balliedier A, Greig NH, Rogers JT. The Anticholinesterase Phenserine and its Enantiomer posiphen as 5’Untraslated–region –directed Translation Blockers of the Parkinson,s Alpha Synuclein Expression. Parkinsons disease 2012, doi:10.1155/2012/142372

Collier KS, Maries E, kordower JH. Etiology of parkinson’s disease: Genetics and environment revisited. Proc Natl Acad Sci U S A 2002; 99: 13972-4

Vekrellis K, Xilouri M, Emmanouilidou E, Rideout H, Stefanis E. Pathological roles of Alpha-Synuclein in neurological disorders. Neurology 2011; 10: 1015-25.

KathleenA. Maguire-Zeiss. α-Synuclein: A therapeutic target for parkinson’s disease?. Pharmacol Res. 2008; 58:271-280

Sidhu A, Wersinger C, Charbel EH. Moussa, Vernier P. The role of α-Synuclein in both Neuroprotection and Neurogeneration. Ann. N.Y. Acad. Sci. 2004 ;1035: 250–270.

Maries E, Dass B, Collier TJ, Kordower JH, Collier KS. The Role of α-Synuclein in Parkinson’s Disease: Insights From Animal Models. Nat Rev Neurosci 2003; 4 :727-737.

Sidhu A, Wersinger C, Vernier P. Does α-Synuclein modulate dopaminergic synaptic content and tone at the synapse? The FASEB Journal. 2004; 18: 637-647.

Omar MA, El-Agnaf, Katerina E. Paleologou, Greer B, Abdulmawala M et al. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB Journal. 2004; 1-34.

Ono K, Yamada M. Antioxidant compounds have potent anti fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Journal of Neurochemistry 2006; 97: 105–115.

Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC et al. Anti –Parkinsonian drug discovery from herbal medicines: what have we got from neutotoxic models? Journals of Ethnopharmacology 2012; 139: 698-711.

Srivastava V, Kumar A, Mishra BN, Siddiqi MI. Molecular docking studies on DMDP derivatives as human DHF inhibitors. Bioinformation 2008; 3:180-188.

Tsigelny IF, Sharikov Y, Miller MA, Maasliah E. Mechanism of Alpha-Synuclein Oligomerization and Membrane Interaction: Theortical Approach To Unstructured Proteins Studies. Nanomedicine 2008; 4 :350-357.

Lipinski CA, Franco I, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3–25.

Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures J.Appl. Cryst 1993; 26 :283–291.

Seal A, Aykkal R, Babu RO, Ghosh M. Docking Study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 2011; 5: 430-439.

Momany FA, Rone RJ. Validation of the general purpose QUANTA 3.2/CHARMm force field. Comp. Chem 1992; 13: 888-900.

Srivastava V, Gupta SP, Siddqi MI Mishra BN. Molecular docking studies on quinazoline antifolate derivates as human thymidylate synthase inhibitors. Bioinformation 2010; 4(8): 357-366

Daisy P, Rajalakshmi M, Lilly V, Anusta S. A Computational approach for the identification of anti-HIV phytocompounds with respect to T-cell receptor through molecular docking. Der Pharma Chemica 2011; 3:18-31.

Cheng A, Merz JK Journal of medicine chemistry 2003; 46: 3572- 3580.

Susnow RG, Dixon SL. Use of robust classification techniques for the prediction of human Cytochrome P450 2D6 inhibition. Journal of chemical information and computer science 2003; 43: 1308-1315.

Pitchai D, Manikkam R, Sr Lilly V, Singaram R. Structure based virtual screening of anticanerous polyphenolic phytocompounds against G-Protein coupled recepor and identification of potent antagonist ligands through molecular docking. Bioinformation 2011; 6(6):226-228.

Hamsa NS , Vandana PN , Vivek Chandramohan , Seema JP. Pharmacophore elucidation and docking studies on anti-inflammatory compounds of medicinal plants for ulcerative colitis. Asian journal of pharmaceutical and clinical research 2013; 6(3): 56-61.

Thangathirupathi A, Naushad Ali, Natarajan P, Ramesh Kumar. Molecular Docking Studies of Andrographolide with Xanthine Oxidase. Asian journal of pharmaceutical and clinical research 2013; 6(2): 300-302.



How to Cite

.L. JAYARAJ, R., V. Ranjani, K. Manigandan, and N. Elangovan. “INSILICO DOCKING STUDIES TO IDENTIFY POTENT INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION IN PARKINSON DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 8, Sept. 2013, pp. 127-31,